Schizophrenia guidelines across the world: A selective review and comparison

References

• AGREE (2009). The AGREE II instrument. Available at www.agreetrust.org
   Google Scholar
• AGREE Collaboration (2001). Appraisal of Guidelines for Research and Evaluation (AGREE) instrument. Available at www.agreecollaboration.org.
   Google Scholar
• AGREE Collaboration (2003a). Appraisal of Guidelines for Research and Evaluation (AGREE) instrument and training material. Available at www.agreecollaboration.org.
   Google Scholar
• AGREE Collaboration (2003b). Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. Quality and Safety in Health Care, 12, 18–23.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA) (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161, S1–56.
   Google Scholar
• Birchwood, M., Todd, P. & Jackson, C. (1998). Early intervention in psychosis. The critical period hypothesis. British Journal of Psychiatry, 172, S53–59.
   PubMedGoogle Scholar
• Brouwers, M.C., Kho, M.E., Browman, G.P., Burgers, J.S., Cluzeau, F., Feder, G., ...AGREE Next Steps Consortium (2010). AGREE II: Advancing guideline development, reporting and evaluation in health care. Canadian Medical Association Journal, 182, E839–842.
   PubMed Web of Science ®Google Scholar
• Fervers, B., Burgers, J.S., Voellinger, R., Brouwers, M., Browman, G.P., Graham, I.D., The ADAPTE Collaboration (2011). Guideline adaptation: An approach to enhance efficiency in guideline development and improve utilisation. Quality and Safety in Health Care, 20, 228–236.
   Google Scholar
• Field, M.J. & Lohr, K.N. (1992). Guidelines for Clinical Practice: From Development to Use. Washington, DC: Institute of Medicine, National Academy Press. P. 2.
   Google Scholar
• Gaebel, W., Falkai, P., Weinmann, S. & Wobrock, T. (2005a). Behandlungsleitlinie Schizophrenie [Schizophrenia treatment guideline]. In: Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Eds). S3 Praxisleitlinien in Psychiatrie und Psychotherapie. [S-3-Practice Guidelines in Psychiatry and Psychotherapy] Darmstadt: Steinkopf Verlag,
   Google Scholar
• Gaebel, W., Weinmann, S., Sartorius, N., Rutz, W. & McIntyre, J.S. (2005b). Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry, 187, P. 248.
   PubMed Web of Science ®Google Scholar
• Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., Möller, H.J. (2007). Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry, 68, 1763–1774.
   PubMedGoogle Scholar
• Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., German Study Group on First-Episode Schizophrenia (2011). Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry, 72, 205–218.
   PubMed Web of Science ®Google Scholar
• Gaebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Smeraldi, E. (2010). Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: Results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology, 35, 2367–2377.
   PubMed Web of Science ®Google Scholar
• Grimshaw, J.M., Thomas, R.E., MacLennan, G., Fraser, C., Ramsay, C.R., Vale, L., Donaldson, C. (2004). Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment, 8, iii–iv, 1–72.
   PubMed Web of Science ®Google Scholar
• Jobe, T.H. & Harrow, M. (2005). Long-term outcome of patients with schizophrenia: A review. Canadian Journal of Psychiatry, 50, 892–900.
   PubMed Web of Science ®Google Scholar
• Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 63(10), 1079–87.
   PubMed Web of Science ®Google Scholar
• Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P., EUFEST study group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet, 371, 1085–1097.
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl, J., Buchanan, R.W., Dickerson, F.B. & Dixon, L.B.; Schizophrenia Patient Outcomes Research Team (PORT) (2010). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2009. Schizophrenia Bulletin, 36, 94–103.
   PubMed Web of Science ®Google Scholar
• Lehman, A.F. & Steinwachs, D.M. (1998). Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1–10.
   PubMed Web of Science ®Google Scholar
• Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C. & Davis, J.M. (2009a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373, 31–41.
   PubMed Web of Science ®Google Scholar
• Leucht, S., Kissling, W. & Davis, J.M. (2009b). Second-generation antipsychotics for schizophrenia: Can we resolve the conflict? Psychological Medicine, 39, 1591–1602.
   PubMed Web of Science ®Google Scholar
• Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K. (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–23.
   PubMed Web of Science ®Google Scholar
• Lugtenberg, M., Burgers, J.S. & Westert, G.P. (2009). Effects of evidence-based clinical practice guidelines on quality of care: A systematic review. Quality and Safety in Health Care, 18, 385–392.
   PubMed Web of Science ®Google Scholar
• McGorry, P., Killackey, E., Elkins, K., McGorry, P., Killackey, E., Elkins, K. RANZCP Clinical Practice Guideline Team for the Treatment of Schizophrenia (2003). Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australasian Psychiatry, 11, 136–147.
   Google Scholar
• Menezes, N.M., Arenovich, T. & Zipursky, R.B. (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine, 36, 1349–1362.
   PubMed Web of Science ®Google Scholar
• Möller, H.J., Riedel, M., Jäger, M., Wickelmaier, F., Maier, W., Kühn, K.U., Gaebel, W. (2008). Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. International Journal of Neuropsychopharmacology, 11, 985–997.
   PubMed Web of Science ®Google Scholar
• Murray, C.J.L. & Lopez, A.D. (1996). The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, Harvard School of Public Health on behalf of the World Health Organization and the World Bank.
   Google Scholar
• NICE (2002). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care.. NICE Clinical Guideline 1.. London: National Institute for Health and Clinical Excellence. Available at www.nice.org.uk.
   Google Scholar
• NICE (2007). The Guidelines Manual. London: National Institute for Health and Clinical Excellence. NICE Clinical guideline Available at www.nice.org.uk
   Google Scholar
• NICE (2009). Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. NICE Clinical Guideline 82. London: National Institute for Health and Clinical Excellence. Available at http//guidance.nice.org.uk/CG82.
   Google Scholar
• Ollenschläger, G., Marshall, C., Qureshi, S., Rosenbrand, K., Burgers, J., Mäkelä, M., Board of Trustees 2002, Guidelines International Network (G-I-N) (2004). Improving the quality of health care: Using international collaboration to inform guideline programmes by founding the Guidelines International Network (G-I-N). Quality and Safety in Health Care, 13, 455–460.
   PubMedGoogle Scholar
• Rosenheck, R.A., Krystal, J.H., Lew, R., Barnett, P.G., Fiore, L., Valley, D., CSP555 Research Group (2011). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine, 364, 842–851.
   PubMed Web of Science ®Google Scholar
• Royal Australian and New Zealand College of Psychiatrists (RANZCP) (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39, 1–30.
   PubMedGoogle Scholar
• Tandon, R., Nasrallah, H.A. & Keshavan, M.S. (2010). Schizophrenia, ‘Just the facts’ 5. Treatment and prevention. Past, present, and future. Schizophrenia Research, 122, 1–23.
   PubMed Web of Science ®Google Scholar
• Watt, D.C., Katz, K. & Shepherd, M. (1983). The natural history of schizophrenia: A 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment. Psychological Medicine, 13, 663–670.
   PubMed Web of Science ®Google Scholar
• Weinmann, S., Koesters, M. & Becker, T. (2007). Effects of implementation of psychiatric guidelines on provider performance and patient outcome: Systematic review. Acta Psychiatria Scandinavica, 115, 420–433.
   PubMedGoogle Scholar
• WHO (2008). The global burden of disease: 2004 update. Geneva: World Health Organization.
   Google Scholar
• Wobrock, T., Weinmann, S., Falkai, P. & Gaebel, W. (2009). Quality assurance in psychiatry: Quality indicators and guideline implementation. European Archives of Psychiatry and Clinical Neuroscience, 259, S219–226.
   PubMed Web of Science ®Google Scholar
• Wölwer, W., Buchkremer, G., Häfner, H., Klosterkötter, J., Maier, W., Möller, H.J. & Gaebel, W. (2003). German Research Network on Schizophrenia – Bridging the gap between research and care. European Archives of Psychiatry and Clinical Neuroscience, 253, 321–329.
   PubMed Web of Science ®Google Scholar